Batanopride (BMY-25801): A new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis

L. Smaldone, P. Plezia, D. Alberts, M. Aapro, G. Sartiano, M. Dorn, M. Brady, C. Comerski, S. E. Schwartz, C. Fairchild, R. Canetta, M. Rozencweig

Research output: Contribution to journalArticle

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)319-327
Number of pages9
JournalCancer Treatment Reviews
Volume17
Issue number2-3
DOIs
StatePublished - Sep 1990

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Smaldone, L., Plezia, P., Alberts, D., Aapro, M., Sartiano, G., Dorn, M., Brady, M., Comerski, C., Schwartz, S. E., Fairchild, C., Canetta, R., & Rozencweig, M. (1990). Batanopride (BMY-25801): A new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis. Cancer Treatment Reviews, 17(2-3), 319-327. https://doi.org/10.1016/0305-7372(90)90064-M